<DOC>
	<DOCNO>NCT00923663</DOCNO>
	<brief_summary>The activity monotherapy Lenalidomide evaluate patient lymphoma mucosa associate lymphoid tissue ( MALT ) .</brief_summary>
	<brief_title>Trial Lenalidomide Patients With Lymphoma Mucosa Associated Lymphoid Tissue ( MALT ) Type</brief_title>
	<detailed_description>The primary objective study evaluate clinical potential Lenalidomide induce objective/histologic response patient MALT lymphoma . The secondary objective evaluate safety Lenalidomide patient population evaluate impact Lenalidomide progression free survival .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Patients histologically confirm MALT lymphoma measurable disease ( stage I IV ) With first great relapse HPeradication , radiation chemotherapy case gastric lymphoma Age &gt; 18 year Must able tolerate therapy , adequate cardiac , renal , hepatic function , ECOG status 0 2 Must capable understand purpose study give write informed consent Lymphoma histology MALT lymphoma MALT lymphoma diffuse large cell lymphoma ( `` high grade lymphoma '' ) component Use investigational agent within 28 day prior initiation treatment lenalidomide History malignancy squamous cell carcinoma , basal cell carcinoma skin carcinoma situ cervix within last 5 year Major surgery , diagnostic surgery , within last 4 week Evidence CNS involvement A history uncontrolled seizure , central nervous system disorder psychiatric disability judge investigator clinically significant adversely affect compliance study drug Severe peripheral polyneuropathy Clinically significant cardiac disease ( e.g. , congestive heart failure , symptomatic coronary artery disease cardiac arrhythmia well controlled medication ) myocardial infarction within last 6 month Inadequate hematological status baseline prior study entry : Dependency red blood cell and/or platelet transfusion , ANC ( absolute neutrophil count ( segment + band ) ) &lt; 1.0 x 109/L Patients active opportunistic infection Pregnancy Uncontrolled diabetes mellitus Preexisting thromboembolic event start study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>MALT lymphoma</keyword>
	<keyword>Advanced Helicobacter pylori-refractory MALT lymphoma</keyword>
</DOC>